University of Charleston
Scott Weston
Contact Info

gradyweston@ucwv.edu

304-357-4859

Dean, UC School of Pharmacy

  • Master of Business Administration, Harding University, 2018
  • Postdoctoral Research Fellow, Northwestern University Medical School, 1998
  • Ph.D., Medicinal/Pharmaceutical Chemistry, University of Mississippi, 1995
  • B.S., Pharmacy, University of Mississippi, 1990

 

  • 2011— 2012: Academic Leadership Fellow, American Association of Colleges of Pharmacy
  • 1995: U. M. Dept. of Medicinal Chemistry Graduate Research Award
  • 1994: U. M. Dept. of Medicinal Chemistry Graduate Research Award
  • 1993: U. M. Dept. of Medicinal Chemistry Graduate Research Award
  • 1992: U. M. School of Pharmacy Graduate Research Award
    (Outstanding Graduate Student in the School of Pharmacy)
  • 1990: Glaxo/AFPE/AACP Graduate Studies Scholarship
  • 1990: Mylan Excellence in Pharmacy Award
  • 1984 – 1986: U. M. University Honors Program
  • 1984 – 1988: Carrier Scholarship (full undergraduate scholarship)

  • 2002: Shoichet, B.K & Weston, G.S. Inhibitors of ß-Lactamases and
    Uses Therefore. US6448238.
  • 2002: Shoichet, B.K & Weston, G.S. Inhibitors of ß-Lactamases and
    Uses Therefore. US6417174.
  • 2001: Shoichet, B.K & Weston, G.S. Inhibitors of ß-Lactamases and
    Uses Therefore. US6184363.
  • 2000: Shoichet, B.K & Weston, G.S. Inhibitors of ß-Lactamases and
    Uses Therefore. EP1009415.
  • 2000: Shoichet, B.K & Weston, G.S. Inhibitors of ß-Lactamases and
    Uses Therefore. US6075014
  • 1998: Shoichet, B.K & Weston, G.S. Inhibitors of ß-Lactamases and
    Uses Therefore. WO9856392.

*Corresponding/primary author

Weston GS*, Roberts, AM, Kamdem LK. The pharmacogenetics
of drug metabolism. In Zdanowicz MM, ed. Concepts in
Pharmacogenomics, 2nd Edition. Bethesda, MD: ASHP
Publications; 2017

Cisneros RM*, Jawaid SP, Kendall DA, McPherson CE, Mu K,
Weston GS, Roberts KB. International practice experiences in
pharmacy education. Am J Pharm Educ. 2013; 77: 1-6

Weston GS*, McGuire JM. U.S. can’t afford to ignore mentally ill.
The Tennessean. October 24, 2013

Weston GS*, Yeboah KG. Site-specific drug delivery to the
gastrointestinal tract. J Mol Pharm Org Process Res. 2013; 1:e106 (2013)

Weston GS.* The pharmacogenetics of drug metabolism. In
Zdanowicz MM, ed. Concepts in Pharmacogenomics. Bethesda,MD: ASHP Publications; 2010: 85-128

Zdanowicz MM,* Huston SA, Weston GS. Pharmacogenomics in
the professional pharmacy curriculum: Content, presentation and
importance. Int J Pharm Educ. 2006; 3:1-12

Choe Y, Brinen LS, Price MS, Engel JC, Lange M, Grisostomi C,
Weston GS, Pallai PV, Cheng H, Hardy LW, Hartsough DS,
McMakin M, Tilton RF, Baldino CM, Craik CS.* Development of
a-keto-based inhibitors of cruzain, a cysteine protease
implicated in Chagas’ Disease. Bioorg Med Chem. 2005;
13:2141-2156

Woolfrey JR,* Weston GS. The use of computational methods in
the discovery and design of kinase inhibitors. Curr Phct Design.
2002; 8:1527-1545

Su AI, Lorber DM, Weston GS, Baase WA, Matthews BW,
Shoichet BK.* Docking molecules by families to increase the
diversity of hits in database screens: Computational strategy
and experimental evaluation. Proteins: Structure, Function, and
Bioinformatics. 2001; 42:279-283

Weston GS,* Cheng H, Madler M, Gristostomi C, Lange M, Pallai,
P, Hardy L, Hartsough DS, Tilton RS. Structure-biased design of
novel alpha-ketoamide inhibitors of cruzain, a cysteinyl protease
involved in Chagas’ Disease. In Holtje HD, Sippl W, eds.
Rational Approaches to Drug Design: Proceedings of the 13th
European Symposium on Quantitative Structure-Activity
Relationships. Barcelona: Prous Science; 2001: 65-68

Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F,
Shoichet BK.* The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci. 1999; 8:2330-2337

Weston GS, Blazquez J, Baquero F, Shoichet BK.* Structurebased enhancement of boronic acid-based beta-lactamase inhibitors. J Med Chem. 1998; 41:4577-4586

Usher KC, Blaszczak LC, Weston GS, Shoichet BK,* Remington,
SJ.* The three-dimensional structure of AmpC beta-lactamase
from Escherichia coli bound to a transition-state analog: Possible
implications for the oxyanion hypothesis and for inhibitor design.
Biochemistry. 1998; 37:16082-16092

Weston GS, Sindelar RD.* Granzymes as targets for rational
drug design. Curr Med Chem. 1996; 3:37-46.